[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, saracatinib has been tested in clinical trials. Document [0] mentions that saracatinib has been researched for applications such as Alzheimer's disease. Document [3] states that a clinical trial will test the potential benefit of AZD0530 (saracatinib) for Alzheimer's disease modification. Document [4] describes a randomized, double-blinded, placebo-controlled, phase 2.5 study of saracatinib in patients with recurrent osteosarcoma localized to the lung. Document [9] mentions a phase I/II study of saracatinib in combination with gemcitabine in patients with advanced pancreatic cancer. Document [10] discusses a phase II study of saracatinib in patients with advanced thymic malignancies. Document [13] describes a phase II study of saracatinib in patients with previously treated metastatic colorectal cancer. Document [14] mentions a phase II study of saracatinib in patients with metastatic or locally advanced gastric or gastroesophageal junction adenocarcinoma. Document [19] discusses a phase II trial of saracatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma. Document [21] mentions a phase II trial of saracatinib in patients with extensive stage small cell lung cancer. Document [27] describes a phase II trial of saracatinib in patients with metastatic melanoma. Document [29] mentions a phase II trial of saracatinib in previously-treated advanced non-small-cell lung cancer. Document [30] discusses the association between PIK3CA mutations and sensitivity to saracatinib in colorectal cancer. Document [31] describes the efficacy of saracatinib in a mouse model of fibrodysplasia ossificans progressiva. Based on this information, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]